LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.21 -0.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.2

Máximo

31.23

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.542 51.415
BPA	0.68
Margen de beneficios	42.663
Empleados	182
EBITDA	-7.8M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+6.06% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	271M 3.8B
Apertura anterior	31.24
Cierre anterior	31.21

Noticias sobre sentimiento de mercado

By Acuity

50%

174 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 may 2026, 22:02 UTC

Ganancias

ZTO Express (Cayman): Di Xu to Resign From Board

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 may 2026, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 may 2026, 21:37 UTC

Ganancias

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 may 2026, 21:01 UTC

Ganancias

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 may 2026, 20:58 UTC

Ganancias

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 may 2026, 20:46 UTC

Acciones populares

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 may 2026, 20:43 UTC

Charlas de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 may 2026, 20:34 UTC

Ganancias

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q EPS 5c >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q Sales $1.4B >JHX

19 may 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5B

19 may 2026, 20:18 UTC

Charlas de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 may 2026, 19:23 UTC

Charlas de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

6.06% repunte

Estimación a 12 Meses

Media 33.1 USD 6.06%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

174 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.